Safety and Effectiveness of Midline CathetersNCT07677696
Evaluating Midline Catheters in Clinical Practice
An observational study of Safety and Effectiveness of Midline Catheters and Vascular Access Devices, run by Shandong Branden Med.Device Co.,Ltd at 1 site in China.
Trial summary
The goal of this observational study is to learn about the safety and effectiveness of midline catheters in patients who receive midline catheter placement as part of their routine clinical care. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Safety and Effectiveness of Midline Catheters, Vascular Access Devices
- What is being tested?
- Midline catheter placement
- Type of treatment
- Injection or infusion, Medical device
- How many people
- 10,000 participants
- Where
- 1 siteChina
- Study dates
- 1 May 2026to 1 May 2027
- How long will I take part?
- 28 Days
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients aged 18 years or older receiving a first-time midline catheter as part of their routine clinical care for intravenous therapy expected to last 1 to 4 weeks.
Who may be able to join
- Age ≥ 18 years
- First-time midline catheter placement per physician order
- Not enrolled in another clinical study
- Willing and able to provide informed consent and comply with follow-up (unless consent waived by local ethics committee)
Who cannot join
- Deemed unsuitable by investigator (e.g., poor compliance or inability to communicate clearly)
- Refusal of informed consent by patient or family member
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Zibo Central Hospital
Zibo
Lina Zhang, +86 18678187002, 1173565974@qq.com
About this study
Official title: A Prospective, Multicenter, Real-World Clinical Study Provides an Assessment of the Safety and Efficacy of Midline Catheters
The goal of this observational study is to learn about the safety and effectiveness of midline catheters in patients who receive midline catheter placement as part of their routine clinical care. The main question it aims to answer is:
Do midline catheters demonstrate acceptable safety and effectiveness when used in routine clinical practice?
Participants who receive a midline catheter as part of their regular medical care will have their clinical data collected from electronic medical records and patient questionnaires, and followed for outcomes related to catheter-related complications and functional performance.
Read the detailed description
Study Title
A prospective multicenter real-world clinical study provides an assessment of the safety and efficacy of midline catheters
Study Description
Background and Why This Study Is Being Done
Midline catheters are intended for patients expected to require intravenous therapy for 1 to 4 weeks. They offer several advantages including rapid insertion, a high safety profile, low maintenance costs, and no need for X-ray confirmation of tip placement. Although midline catheters are widely used in clinical practice internationally, their adoption in China has been relatively late. Research on midline catheters in China remains limited and in its early stages without in-depth investigation.
This large-scale prospective multicenter real-world study, therefore, aims to provide robust data on the actual clinical use, safety, and effectiveness of midline catheters in China. The findings will support the standardization of midline catheter promotion, improvement, and operational and maintenance protocols.
Study Objectives
This study has two primary objectives. The first is to evaluate the real-world clinical application, safety, and effectiveness of midline catheters in China. The second is to identify risk factors associated with midline catheter-related complications, thereby defining target populations for focused intervention and providing evidence-based guidance for the development of preventive strategies.
Overall Study Design
This is a prospective multicenter observational real-world study. It plans to enroll approximately 10,000 patients receiving a midline catheter across 40 hospitals nationwide. Participants will be followed until catheter removal with observation and documentation of any complications occurring during the catheter dwell time.
Data analysis will include patient baseline characteristics, complication data, and catheter application data. These data will be used to evaluate the clinical safety and effectiveness of midline catheters. Logistic regression analysis will be performed to explore risk factors for complications. In addition, descriptive analysis of indications, catheter dwell time, and insertion and maintenance costs will help characterize the most common applications, the average dwell time, and the associated expenses.
Who Can Participate (Eligibility Criteria)
Inclusion criteria are being age 18 years or older, receiving a midline catheter for the first time as prescribed by a physician, not currently participating in any other clinical study, being alert and oriented with willingness to voluntarily participate and sign informed consent (unless the local ethics committee waives the consent requirement), and having the ability to comply with follow-up.
Exclusion criteria include being deemed unsuitable for participation by the investigator (for example due to poor compliance or inability to communicate clearly) or the patient or family member refusing to sign informed consent.
Study Endpoints
The study will assess the following outcomes. "Catheter-related complication rate" refers to the frequency of complications such as infection, occlusion, and thrombosis. Catheter function rate is the proportion of catheters functioning as intended without failure. One-time insertion success rate means successful placement on the first attempt. Catheter dwell time is the duration from insertion to removal. Unplanned removal rate indicates premature removal due to complications or failure. Insertion and maintenance costs are the total expenses associated with catheter placement and care. Patient satisfaction is the patient-reported satisfaction with the catheter experience.
Observation Period and Follow-Up Schedule
Follow-up assessments will occur during routine maintenance visits at the following time points if the catheter remains in place. These time points are 7 ± 3 days post-insertion, 14 ± 3 days post-insertion, 21 ± 3 days post-insertion (if applicable), and 28 ± 3 days post-insertion (if applicable). For catheters remaining in place beyond 28 days, follow-up will continue at each routine maintenance visit until removal. A participant is considered to have completed the study when the catheter is removed either because treatment has ended or due to a complication. Participants do not need to complete all scheduled follow-up time points.
Data Source
Study data will be collected through case report forms from multiple sources, including hospital electronic medical record systems, laboratory test results, outpatient prescription records, catheter maintenance records, insertion and maintenance cost data, and patient-completed questionnaires.
Sample Size and Rationale
This study is a prospective observational study rather than a standard interventional clinical trial. As such, the sample size is not based on a statistical calculation or a predetermined number. Instead, enrollment is limited to patients who meet all inclusion criteria, have no exclusion criteria, and actually receive a midline catheter at a participating hospital during the study period. The study expects to enroll approximately 10,000 midline catheter recipients across 40 hospitals nationwide.
- Being tested
- Midline catheter placement
- Keywords
- Midline catheters, vascular access devices, catheter-related complications, patient safety, real-world study
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Midline catheter placementDevice
Patients receive a midline catheter as part of their routine clinical care for intravenous therapy lasting 1 to 4 weeks
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants With Catheter-Related Complications
Catheter-related complications include phlebitis, catheter-related bloodstream infection (CRBSI), venous thrombosis, and catheter occlusion. Complication rate is calculated as the number of participants experiencing at least one complication divided by the total number of enrolled participants, multiplied by 100 percent.
Measured: From catheter insertion until removal, assessed up to 28 days
Secondary outcomes (6)
Catheter Function Rate
Catheter function rate is defined as the proportion of participants whose catheter remains functional without any complications until removal. It is calculated as the number of participants with no complications and with functional catheter at removal divided by the total number of enrolled participants, multiplied by 100 percent.
Measured: At catheter removal, assessed up to 28 days
One-Time Insertion Success Rate
One-time insertion success is defined as successful placement of the catheter tip at the ideal position (axillary vein thoracic segment or subclavian vein) on the first attempt without need for repositioning, with the catheter functioning normally for infusion. The rate is calculated as the number of participants with one-time insertion success divided by the total number of enrolled participants, multiplied by 100 percent.
Measured: At catheter insertion, assessed up to 28 days
Catheter Dwell Time
Catheter dwell time is defined as the duration in days from successful catheter placement to catheter removal.
Measured: From catheter insertion to removal, assessed up to 28 days
Unplanned Removal Rate
Unplanned removal is defined as premature catheter removal due to complications or other causes before the planned completion of intravenous therapy. The rate is calculated as the number of participants with unplanned removal divided by the total number of enrolled participants, multiplied by 100 percent.
Measured: From catheter insertion to removal, assessed up to 28 days
Insertion and Maintenance Cost
Insertion and maintenance cost includes all expenses associated with catheter placement (device cost, insertion procedure, anesthesia, ultrasound guidance if used) and catheter care (dressing changes, flushing, site care, and complication management).
Measured: From catheter insertion to removal, assessed up to 28 days
Patient Satisfaction
Patient satisfaction is assessed at catheter removal using a 5-point Likert scale (1=very dissatisfied, 2=dissatisfied, 3=neutral, 4=satisfied, 5=very satisfied). The satisfaction rate is calculated as the number of participants rating 4 or 5 divided by the total number of participants who completed the survey, multiplied by 100 percent.
Measured: At catheter removal, , assessed up to 28 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Jul 2026
- Study start1 May 2026
- Primary completion1 May 2027 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Safety and Effectiveness of Midline CathetersStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 10,000 participants (estimated)
- Target duration
- 28 Days
Sponsor and investigators
- Lead sponsor
- Shandong Branden Med.Device Co.,Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Zibo Central Hospital
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07677696
- Sponsor's protocol ID
- Branden-MRW2023
- Status last verified
- Jun 2026
- First submitted
- 13 Jun 2026
- Last updated
- 1 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Prospective, Multicenter, Real-World Clinical Study Provides an Assessment of the Safety and Efficacy of Midline Catheters
- ClinicalTrials.gov ID
- NCT07677696
- Acronym / sponsor ID
- Branden-MRW2023
- Keywords
- Midline catheters, vascular access devices, catheter-related complications, patient safety, real-world study
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 10,000 participants (estimated)
- Lead sponsor
- Shandong Branden Med.Device Co.,LtdIndustry (pharma, biotech, devices)
- Collaborators
- Zibo Central Hospital
- Study start
- 1 May 2026 (actual)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 1 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this observational study is to learn about the safety and effectiveness of midline catheters in patients who receive midline catheter placement as part of their routine clinical care. The main question it aims to answer is:
Do midline catheters demonstrate acceptable safety and effectiveness when used in routine clinical practice?
Participants who receive a midline catheter as part of their regular medical care will have their clinical data collected from electronic medical records and patient questionnaires, and followed for outcomes related to catheter-related complications and functional performance.
Detailed description
Study Title
A prospective multicenter real-world clinical study provides an assessment of the safety and efficacy of midline catheters
Study Description
Background and Why This Study Is Being Done
Midline catheters are intended for patients expected to require intravenous therapy for 1 to 4 weeks. They offer several advantages including rapid insertion, a high safety profile, low maintenance costs, and no need for X-ray confirmation of tip placement. Although midline catheters are widely used in clinical practice internationally, their adoption in China has been relatively late. Research on midline catheters in China remains limited and in its early stages without in-depth investigation.
This large-scale prospective multicenter real-world study, therefore, aims to provide robust data on the actual clinical use, safety, and effectiveness of midline catheters in China. The findings will support the standardization of midline catheter promotion, improvement, and operational and maintenance protocols.
Study Objectives
This study has two primary objectives. The first is to evaluate the real-world clinical application, safety, and effectiveness of midline catheters in China. The second is to identify risk factors associated with midline catheter-related complications, thereby defining target populations for focused intervention and providing evidence-based guidance for the development of preventive strategies.
Overall Study Design
This is a prospective multicenter observational real-world study. It plans to enroll approximately 10,000 patients receiving a midline catheter across 40 hospitals nationwide. Participants will be followed until catheter removal with observation and documentation of any complications occurring during the catheter dwell time.
Data analysis will include patient baseline characteristics, complication data, and catheter application data. These data will be used to evaluate the clinical safety and effectiveness of midline catheters. Logistic regression analysis will be performed to explore risk factors for complications. In addition, descriptive analysis of indications, catheter dwell time, and insertion and maintenance costs will help characterize the most common applications, the average dwell time, and the associated expenses.
Who Can Participate (Eligibility Criteria)
Inclusion criteria are being age 18 years or older, receiving a midline catheter for the first time as prescribed by a physician, not currently participating in any other clinical study, being alert and oriented with willingness to voluntarily participate and sign informed consent (unless the local ethics committee waives the consent requirement), and having the ability to comply with follow-up.
Exclusion criteria include being deemed unsuitable for participation by the investigator (for example due to poor compliance or inability to communicate clearly) or the patient or family member refusing to sign informed consent.
Study Endpoints
The study will assess the following outcomes. "Catheter-related complication rate" refers to the frequency of complications such as infection, occlusion, and thrombosis. Catheter function rate is the proportion of catheters functioning as intended without failure. One-time insertion success rate means successful placement on the first attempt. Catheter dwell time is the duration from insertion to removal. Unplanned removal rate indicates premature removal due to complications or failure. Insertion and maintenance costs are the total expenses associated with catheter placement and care. Patient satisfaction is the patient-reported satisfaction with the catheter experience.
Observation Period and Follow-Up Schedule
Follow-up assessments will occur during routine maintenance visits at the following time points if the catheter remains in place. These time points are 7 ± 3 days post-insertion, 14 ± 3 days post-insertion, 21 ± 3 days post-insertion (if applicable), and 28 ± 3 days post-insertion (if applicable). For catheters remaining in place beyond 28 days, follow-up will continue at each routine maintenance visit until removal. A participant is considered to have completed the study when the catheter is removed either because treatment has ended or due to a complication. Participants do not need to complete all scheduled follow-up time points.
Data Source
Study data will be collected through case report forms from multiple sources, including hospital electronic medical record systems, laboratory test results, outpatient prescription records, catheter maintenance records, insertion and maintenance cost data, and patient-completed questionnaires.
Sample Size and Rationale
This study is a prospective observational study rather than a standard interventional clinical trial. As such, the sample size is not based on a statistical calculation or a predetermined number. Instead, enrollment is limited to patients who meet all inclusion criteria, have no exclusion criteria, and actually receive a midline catheter at a participating hospital during the study period. The study expects to enroll approximately 10,000 midline catheter recipients across 40 hospitals nationwide.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 28 Days
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients aged 18 years or older receiving a first-time midline catheter as part of their routine clinical care for intravenous therapy expected to last 1 to 4 weeks.
Key inclusion criteria (4 listed)
- Age ≥ 18 years
- First-time midline catheter placement per physician order
- Not enrolled in another clinical study
- Willing and able to provide informed consent and comply with follow-up (unless consent waived by local ethics committee)
Key exclusion criteria (2 listed)
- Deemed unsuitable by investigator (e.g., poor compliance or inability to communicate clearly)
- Refusal of informed consent by patient or family member
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Midline catheter placementPatients receive a midline catheter as part of their routine clinical care for intravenous therapy lasting 1 to 4 weeks | Device | – |
Primary outcome
Number of Participants With Catheter-Related Complications
Time frame: From catheter insertion until removal, assessed up to 28 days
Catheter-related complications include phlebitis, catheter-related bloodstream infection (CRBSI), venous thrombosis, and catheter occlusion. Complication rate is calculated as the number of participants experiencing at least one complication divided by the total number of enrolled participants, multiplied by 100 percent.
6 secondary outcomes
Catheter Function Rate
Time frame: At catheter removal, assessed up to 28 days
One-Time Insertion Success Rate
Time frame: At catheter insertion, assessed up to 28 days
Catheter Dwell Time
Time frame: From catheter insertion to removal, assessed up to 28 days
Unplanned Removal Rate
Time frame: From catheter insertion to removal, assessed up to 28 days
Insertion and Maintenance Cost
Time frame: From catheter insertion to removal, assessed up to 28 days
Patient Satisfaction
Time frame: At catheter removal, , assessed up to 28 days
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jul 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Safety and Effectiveness of Midline Catheters and Vascular Access Devices, run by Shandong Branden Med.Device Co.,Ltd at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 1 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Lina Zhang (+86-18678187002, 1173565974@qq.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants With Catheter-Related Complications (time frame: From catheter insertion until removal, assessed up to 28 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2026.